Menée aux Etats-Unis en 2018 par enquête auprès de 1 872 fumeurs de cigarettes classiques et/ou utilisateurs de la cigarette électronique, cette étude identifie les effets nocifs de la cigarette électronique déjà connus par ces consommateurs et détermine les plus dissuasifs

E-cigarette health harm awareness and discouragement: Implications for health communication

Rohde, Jacob A ; Noar, Seth M ; Mendel, Jennifer R ; Hall, Marissa G ; Baig, Sabeeh A ; Ribisl, Kurt M ; Brewer, Noel T

Evidence for the health harms of e-cigarettes is growing, yet little is known about which harms may be most impactful in health messaging. Our study sought to identify which harms tobacco product users were aware of and which most discouraged them from wanting to vape.Participants were a convenience sample of 1,872 U.S. adult e-cigarette-only users, cigarette-only smokers, and dual users recruited in August 2018. In an online survey, participants evaluated 40 e-cigarette harms from 7 [...]

Menée à l'aide d'un modèle murin de cancer du côlon, cette étude analyse, en fonction de la posologie, l'effet chimiopréventif de l'aspirine associée au naproxène

Intermittent Dosing Regimens of Aspirin and Naproxen Inhibit Azoxymethane-Induced Colon Adenoma Progression to Adenocarcinoma and Invasive Carcinoma

Mohammed, Altaf ; Janakiram, Naveena B. ; Madka, Venkateshwar ; Zhang, Yuting ; Singh, Anil ; Biddick, Laura ; Li, Qian ; Lightfoot, Stanley ; Steele, Vernon E. ; Lubet, Ronald A. ; Suen, Chen S. ; Miller, Mark Steven ; Sei, Shizuko ; Rao, Chinthalapally V.

Chronic use of aspirin and related drugs to reduce cancer risk is limited by unwanted side effects. Thus, we assessed the efficacy associated with different dosing regimens of aspirin and naproxen. Azoxymethane (AOM)-rat colon cancer model was used to establish the pharmacodynamic efficacy of aspirin and naproxen under different dosing regimens. Colon tumors were induced in rats (36/group) by two weekly doses of AOM. At the early adenoma stage, rats were fed diets containing aspirin (700 and [...]

Menée aux Etats-Unis à partir de données de la cohorte "Sister study" portant sur 432 utilisatrices de raloxifène, 96 utilisatrices de tamoxifène et 5 260 témoins, cette étude analyse le rapport bénéfice-risque de ces molécules dans la chimioprévention du cancer du sein

Risk versus Benefit of Chemoprevention among Raloxifene and Tamoxifen Users with a Family History of Breast Cancer

Anderson, Chelsea ; Nichols, Hazel B. ; House, Melissa ; Sandler, Dale P.

Tamoxifen and raloxifene have been approved for the primary prevention of breast cancer in high-risk women, but are associated with an increased risk of serious side effects. Few studies have characterized risk–benefit profiles for chemoprevention among women who initiate tamoxifen or raloxifene outside of a clinical trial setting. Use of raloxifene and tamoxifen for chemoprevention was self-reported in 2014 to 2016 by participants in The Sister Study, a prospective cohort of women with a [...]

Menée au Canada sur la période 2005-2013 par questionnaire auprès de 497 femmes (âge : 18-24 ans) et à l'aide de prélèvements génitaux, cette étude analyse l'effet de la vaccination anti-papillomavirus humain sur la transmission du HPV au sein des couples hétérosexuels

Vaccination of Young Women Decreases Human Papillomavirus Transmission in Heterosexual Couples: Findings from the HITCH Cohort Study

Wissing, Michel D. ; Burchell, Ann N. ; El-Zein, Mariam ; Tellier, Pierre-Paul ; Coutlée, François ; Franco, Eduardo L.

Background : Vaccination against human papillomaviruses (HPV) prevents HPV infections and, consequently, cervical lesions. However, the effect of vaccination on HPV transmission within couples is unknown. Methods : We used data from HITCH, a prospective cohort study of heterosexual couples (women ages 18–24 years) in Montreal, 2005 to 2013. Vaccination history was self-reported. Genital samples were tested for HPV DNA by PCR (linear array). Type-specific viral loads were quantified using [...]